GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biomaxima SA (WAR:BMX) » Definitions » Enterprise Value

Biomaxima (WAR:BMX) Enterprise Value : zł68.38 Mil (As of May. 25, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Biomaxima Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Biomaxima's Enterprise Value is zł68.38 Mil. Biomaxima's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was zł0.80 Mil. Therefore, Biomaxima's EV-to-EBIT ratio for today is 85.91.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Biomaxima's Enterprise Value is zł68.38 Mil. Biomaxima's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was zł3.28 Mil. Therefore, Biomaxima's EV-to-EBITDA ratio for today is 20.82.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Biomaxima's Enterprise Value is zł68.38 Mil. Biomaxima's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was zł46.82 Mil. Therefore, Biomaxima's EV-to-Revenue ratio for today is 1.46.


Biomaxima Enterprise Value Historical Data

The historical data trend for Biomaxima's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomaxima Enterprise Value Chart

Biomaxima Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.02 127.40 127.88 99.52 80.21

Biomaxima Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 99.52 102.81 102.10 86.31 80.21

Competitive Comparison of Biomaxima's Enterprise Value

For the Diagnostics & Research subindustry, Biomaxima's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomaxima's Enterprise Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biomaxima's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Biomaxima's Enterprise Value falls into.



Biomaxima Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Biomaxima's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Biomaxima's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomaxima  (WAR:BMX) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Biomaxima's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=68.384/0.796
=85.91

Biomaxima's current Enterprise Value is zł68.38 Mil.
Biomaxima's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was zł0.80 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Biomaxima's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=68.384/3.284
=20.82

Biomaxima's current Enterprise Value is zł68.38 Mil.
Biomaxima's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was zł3.28 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Biomaxima's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=68.384/46.816
=1.46

Biomaxima's current Enterprise Value is zł68.38 Mil.
Biomaxima's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was zł46.82 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomaxima Enterprise Value Related Terms

Thank you for viewing the detailed overview of Biomaxima's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomaxima (WAR:BMX) Business Description

Traded in Other Exchanges
Address
5 Vetterow Street, Lublin, POL, 20-277
Biomaxima SA is a Polish company, produces microbiology media as well as a wide range of reagents and in Vitro diagnostics equipment. The company is also a distributor of products of recognized global diagnostics companies such as Nova Biomedical, Mitsubishi Chemical and Biologist. Its products include Systems Antibiotic Susceptibility Testing, Urine Analysis Systems, Hematological Reagents along with Analyzers, ion Selective Analyzers with Reagents, Immunological Analyzer of Cardiac markers with reagents, Glucose Meters and analyzers for Gasometric and Critical Blood Tests.

Biomaxima (WAR:BMX) Headlines

No Headlines